Summary
Celltrion reported preliminary third-quarter 2026 revenue of KRW 1.50 trillion and operating profit of KRW 510.0 billion, up 45.8% and 69.2% year on year, respectively.
The implied operating margin reached 34.0%, compared with 29.3% a year earlier and 32.4% in the second quarter.
The result strengthens the case for a more profitable biosimilar business. Newer products are generating a larger share of sales, while manufacturing efficiency and lower inventory costs have supported earnings growth.
Yet the distinction between record profit and sustainable profitability matters.
Celltrion's operating margin was approximately 35.7% in Q4 2025, above the latest preliminary level. The third-quarter achievement is therefore not an unprecedented margin, but a new operating-profit record supported by a larger revenue base.
The investment question is whether Celltrion can maintain that combination of scale and profitability as biosimilar pricing pressure, US reimbursement negotiations and manufacturing investment continue.
Key Takeaways
- ✓ Q3 2026 preliminary revenue reached KRW 1.50 trillion, up 45.8% year on year, while operating profit climbed 69.2% to a quarterly record KRW 510.0 billion.
- ✓ Operating margin increased to 34.0%, up 4.7 percentage points year on year and approximately 1.6 percentage points from Q2 2026.
- ✓ In Q2, newer products accounted for 65% of biologics revenue, and the cost-of-sales ratio declined to 38%. The equivalent Q3 breakdown has not yet been disclosed.
- ✓ Omlyclo launched in the United States on October 5 with preferred formulary placement at Optum. Its US commercial contribution is a future catalyst, not a driver of Q3 earnings.
- ✓ The company needs approximately KRW 516.3 billion in Q4 operating profit to reach its KRW 1.8 trillion full-year objective, based on reported and preliminary figures through September.
What Happened
On October 12, Celltrion announced preliminary consolidated results for the third quarter of 2026.
Revenue increased to KRW 1.50 trillion from KRW 1.029 trillion in Q3 2025.
Operating profit rose to KRW 510.0 billion from KRW 301.4 billion, exceeding KRW 500 billion for the first time in a quarter.
Sequential performance also improved.
Compared with the confirmed Q2 results, revenue rose approximately 7.6%, while operating profit increased 12.9%.
The implied operating margin expanded from 32.4% to 34.0%.
Management attributed the improvement to stronger sales of higher-margin follow-on products and continued production-cost reductions.
Celltrion also exceeded the quarterly operating-profit objectives set earlier in the year for a third consecutive quarter.
Commercial progress was visible across its portfolio.
In Europe, Omlyclo was available in 26 countries and held more than 90% of the Spanish omalizumab market in July, based on local market data cited by the company.
In the United States, established products retained meaningful positions. Celltrion reported August market shares of 39% for Truxima and 31% for Inflectra, while newer products Steqeyma and Yuflyma reached 15% and 11%, respectively.
These market-share figures indicate commercial reach, although they do not directly measure profitability.
A separate development followed the quarter’s end.
Omlyclo entered the US market on October 5 and secured preferred placement on an Optum commercial formulary.
The launch creates an additional growth opportunity from Q4 onward, but its prescription volumes and net commercial contribution remain unproven.
Why It Matters
The significance of Celltrion’s earnings lies in the relationship between product growth and profit conversion.
Biosimilar companies compete on more than regulatory approval or manufacturing capacity.
A successful product must secure market access, gain prescriptions and retain sufficient revenue after discounts, rebates and distribution expenses.
That makes sales growth alone an incomplete measure of business quality.
Celltrion’s recent results indicate that portfolio expansion is increasingly translating into operating leverage.
In Q2 2026, newer products grew 76% year on year and represented 65% of biologics revenue.
The consolidated cost-of-sales ratio fell to 38%, reflecting a combination of favorable product mix, the depletion of higher-cost inventory, better manufacturing yields and process improvements.
These factors have different implications for future earnings.
A higher contribution from competitively positioned products can provide recurring benefits.
Better yields and production efficiency can strengthen the cost base over time.
But the elimination of historically expensive inventory has a finite effect.
Once that process is largely complete, further margin expansion must come from product economics, manufacturing efficiency or operating-expense discipline.
That is the key distinction behind the latest results.
The Q3 preliminary announcement confirms higher consolidated profitability but does not disclose sufficient product-level detail to isolate these drivers.
Investors should therefore view the 34.0% margin as evidence of progress, not yet as a guaranteed long-term earnings baseline.
Celltrion's Q3 results provide credible evidence of a stronger operating model, but the record profit figure is not the entire investment story.
The company has already shown it can achieve margins above 30%. Its challenge is to sustain attractive economics across a broader range of products, regions and reimbursement systems.
The most important potential advantage is the combination of manufacturing integration and a global sales network. As Celltrion introduces additional biosimilars, existing commercial relationships and production infrastructure may reduce the incremental cost of growth.
That advantage is meaningful only if the company retains pricing discipline. Higher volumes obtained through aggressive discounts or costly rebate agreements would weaken the benefit of scale.
Korea Alpha sees the next phase as a test of earnings quality rather than another test of market entry.
The evidence to watch is straightforward: stable product economics, resilient manufacturing costs, profitable US prescription growth and stronger cash generation.
Record earnings establish momentum. Durable returns will determine whether that momentum supports a higher valuation.